News > New drug combination targets prostate cancer on two fronts, study finds

New drug combination targets prostate cancer on two fronts, study finds

Patients with particularly aggressive prostate cancers can be treated more effectively by a combination of existing targeted medicine and an experimental new drug, new research suggests. Researchers discovered that the drug combination of abiraterone and ipatasertib as a first-line treatment reduced the risk of death or cancer progression in those patients by 23 per cent compared with abiraterone alone.

Study leader Johann de Bono, professor of experimental cancer medicine at the ICR and consultant medical oncologist at The Royal Marsden NHS Foundation Trust, said: “We have shown that combining an existing and a new drug to attack cancer on two different fronts can keep men with prostate cancer healthier for longer."